First joint clinical trial of the Ribera Salud and Pratia Foundation for the treatment of early Alzheimer’s disease.

Ribera Salud Foundation and Pratia sign contract for launch first clinical trial the fruit of their strategic alliance, which will study early Alzheimer’s disease in Ribera Powis Hospital (Vigo), under the supervision of a neurologist Jose Ramon Lorenzo Gonzalez.

The clinical trial, “A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Inflammatory Biomarkers,” aims to recruit at least five patientsThe purpose of this study is to “assess the efficacy of the drug in patients with Alzheimer’s disease or mild cognitive impairment.who have inflammation of the brain,” they point out from Ribera Salud. Some participants, they add, will take the drug being studied, while others will take a placebo.

The purpose of this study is to “assess the efficacy of the drug in patients with Alzheimer’s disease or mild cognitive impairment.”

During this period, specialists from the Ribera Powis Hospital will carry out measurements using brain imaging (MRI), blood analysis And cognitive tests patients participating in the study. Upon completion, a 12-month open-label extension is offered during which all participants will receive the study drug.

Implementation of this test this is an important milestone for the promotion of medical research and the benefit of the patient, which the Ribera Salud Foundation and Pratia promote through this collaboration, which also aims to increase patient access to innovative treatments in the three hospitals of the Ribera Group: the University Hospitals of Vinalopó (Elche) and Torrejón (Madrid) and the Ribera Povisa Hospital (Vigo).